mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease

被引:37
|
作者
Belibi, Franck
Ravichandran, Kameswaran
Zafar, Iram
He, Zhibin
Edelstein, Charles L. [1 ]
机构
[1] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO 80262 USA
基金
美国国家卫生研究院;
关键词
cyst volume; kidney size; autosomal dominant polycystic kidney disease; AUTOSOMAL-DOMINANT; CELL-PROLIFERATION; TRANSGENIC MICE; CYST FORMATION; C-MYC; PROGRESSION; ACTIVATION; APOPTOSIS; PATHWAY; KINASE;
D O I
10.1152/ajprenal.00129.2010
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Belibi F, Ravichandran K, Zafar I, He Z, Edelstein CL. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol 300: F236-F244, 2011. First published October 13, 2010; doi: 10.1152/ajprenal.00129.2010.-Rapamycin slows disease progression in the male Han: SPRD (Cy/+) rat with polycystic kidney disease (PKD). The aim of this study was to determine the effect of rapamycin on PKD and the relative contributions of the proproliferative mammalian target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2) in female Cy/+ rats. Female Cy/+ rats were treated with rapamycin from 4 to 12 wk of age. In vehicle-treated Cy/+ rats, kidney volume increased by 40% and cyst volume density (CVD) was 19%. Phosphorylated S6 (p-S6) ribosomal protein, a marker of mTORC1 activity, was increased in Cy/+ rats compared with normal littermate controls (+/+) and decreased by rapamycin. Despite activation of mTORC1 in female Cy/+ rats, rapamycin had no effect on kidney size, CVD, number of PCNA-positive cystic tubular cells, caspase-3 activity, or the number of terminal deoxynucleotidyl transferase dUTP-mediated nick-end label-positive apoptotic cells. To determine a reason for the lack of effect of rapamycin, we studied the mTORC2 signaling pathway. On immunoblot of kidney, phosphorylated (Ser(473)) Akt (p-Akt), a marker of mTORC2 activity, was increased in female Cy/+ rats treated with rapamycin. Phosphorylated (Ser(657)) PKC alpha, a substrate of mTORC2, was unaffected by rapamycin in females. In contrast, in male rats, where rapamycin significantly decreases PKD, p-Akt (Ser(473)) was decreased by rapamcyin. PKC alpha (Ser(657)) was increased in male Cy/+ rats but was unaffected by rapamycin. In summary, in female Cy/+ rats, rapamycin had no effect on PKD and proproliferative p-Akt (Ser(473)) activity was increased by rapamycin. There were differential effects of rapamycin on mTORC2 signaling in female vs. male Cy/+ rats.
引用
收藏
页码:F236 / F244
页数:9
相关论文
共 50 条
  • [31] AGGRAVATION OF POLYCYSTIC KIDNEY-DISEASE (PKD) IN HAN-SPRD RATS BY BUTHIONINE SULFOXIMINE (BSO) AND BY DIETHYLDITHIOCARBAMATE (DTC)
    TORRES, VE
    BENGAL, RJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 711 - 711
  • [32] Selective mTORC1 Inhibitors Block Cystogenesis in a Human Kidney Organoid Model of Polycystic Kidney Disease
    Gulieva, Ramila E.
    Freedman, Benjamin S.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 407 - 407
  • [33] mTORC1 signaling and diabetic kidney disease
    Swaroop, Vinamra
    Ozkan, Eden
    Herrmann, Lydia
    Thurman, Aaron
    Kopasz-Gemmen, Olivia
    Kunamneni, Abhiram
    Inoki, Ken
    DIABETOLOGY INTERNATIONAL, 2024, 15 (04) : 707 - 718
  • [34] Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat
    Schaefer, L
    Han, X
    Gretz, N
    Hafner, C
    Meier, K
    Matzkies, F
    Schaefer, RM
    KIDNEY INTERNATIONAL, 1996, 49 (01) : 75 - 81
  • [35] Enalapril is renoprotective in the Han:SPRD rat model of autosomal dominant polycystic kidney disease (ADPKD).
    Kennefick, TM
    Oyama, TT
    Thompson, MM
    Anderson, S
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1730 - A1730
  • [36] Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease
    Jelena Klawitter
    Iram Zafar
    Jost Klawitter
    Alexander T Pennington
    Jacek Klepacki
    Berenice Y Gitomer
    Robert W Schrier
    Uwe Christians
    Charles L Edelstein
    BMC Nephrology, 14
  • [37] Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease
    Klawitter, Jelena
    Zafar, Iram
    Klawitter, Jost
    Pennington, Alexander T.
    Klepacki, Jacek
    Gitomer, Berenice Y.
    Schrier, Robert W.
    Christians, Uwe
    Edelstein, Charles L.
    BMC NEPHROLOGY, 2013, 14
  • [38] Anti-VEGF treatment accelerates progression of polycystic kidney disease in the Han:SPRD rat
    Shagun, R.
    Wu, M.
    Segerer, S.
    Wuethrich, R. P.
    Serra, A.
    SWISS MEDICAL WEEKLY, 2009, 139 (45-46) : 5S - 5S
  • [39] Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
    Luo, Yan
    Liu, Lei
    Wu, Yang
    Singh, Karnika
    Su, Bing
    Zhang, Nan
    Liu, Xiaowei
    Shen, Yangmei
    Huang, Shile
    ONCOTARGET, 2015, 6 (06) : 4286 - 4298
  • [40] Dissecting the biology of mTORC1 beyond rapamycin
    Yang, Guang
    Francis, Deanne
    Krycer, James R.
    Larance, Mark
    Zhang, Ziyang
    Novotny, Chris J.
    Diaz-Vegas, Alexis
    Shokat, Kevan M.
    James, David E.
    SCIENCE SIGNALING, 2021, 14 (701)